Roche Holding AG Ordinary Shares new
ROP: XSWX (CHE)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| sL! | LOCK|m<% | LOCK|qlJgNHp! |
Roche Earnings: Raising Our FVE to Incorporate Oncology Pipeline Progress
On Oct. 22, Roche reported 7% growth at constant exchange rates (8% pharma, 5% diagnostics) in the third quarter, and management maintained full-year guidance for mid-single-digit sales and high-single-digit core EPS growth, also at constant rates. Shares traded flat.
